We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
- Authors
PATEL, ANUJ K.; ABHYANKAR, RITIKA; BRAIS, LAUREN K.; MEI SHENG DUH; BARGHOUT, VICTORIA E.; HUYNH, LYNN; YENIKOMSHIAN, MIHRAN A.; KIMMIE NG; FUCHS, CHARLES S.
- Abstract
Background. Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with refractory metastatic colorectal cancer (mCRC); limited comparative effectiveness data exist. Materials and Methods. A retrospective, longitudinal cohort study of patients with mCRC who initiated FTD/TPI or regorafenib (index therapy) between 2012 and 2017 at a U.S. tertiary oncology center, Dana-Farber Cancer Institute, was conducted. Using best tumor response assessments, real-world overall response rates (rwORR) and disease control rates (rwDCR) were described and analyzed using logistic regression. Survival rate was examined for each month after index therapy using Kaplan-Meier. Overall survival (OS) was assessed using Cox proportional hazards models. Subgroup analyses among patients with index therapy as second- or third-line were performed. Results. One hundred twenty-six and 95 patients were treated with FTD/TPI or regorafenib as index therapy, respectively. Patients treated with FTD/TPI versus regorafenib had a better response (rwORR 52.5% vs. 34.2%; adjusted odds ratio [OR] = 2.6; all p value <.05; rwDCR 64.2% vs. 46.1%; adjusted OR = 2.5; all p value <.05). Similar findings were observed for FTD/TPI versus regorafenib as second- or third-line therapy (rwORR 54.8% vs. 25.9%; adjusted OR = 4.1; all p value <.05; rwDCR 69.0% vs. 37.0%; adjusted OR = 4.9; all p value <.05). A greater proportion of patients treated with FTD/TPI versus regorafenib survived at 3 months (86.2% vs. 73.4%; p value = .016) and 4 months (79.6% vs. 65.8%; p value = .017). Adjusted OS hazard ratio for FTD/TPI versus regorafenib was 0.80, p value = .157. Conclusion. Patients treated with FTD/TPI had better tumor response and disease control than patients treated with regorafenib. Subgroup analysis in second- or third-line suggests that early use of FTD/TPI may have clinical benefits.
- Subjects
DEOXYRIBONUCLEOSIDES; ANTINEOPLASTIC agents; METASTASIS; RETROSPECTIVE studies; TERTIARY care; CANCER patients; COLORECTAL cancer; HOSPITAL wards; KAPLAN-Meier estimator; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; ODDS ratio; LONGITUDINAL method; ONCOLOGY; PROPORTIONAL hazards models; DOSE-response relationship in biochemistry
- Publication
Oncologist, 2021, Vol 26, Issue 12, pe2161
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1002/onco.13942